# Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

> **NCT00979017** · PHASE2 · COMPLETED · sponsor: **Katy Peters** · enrollment: 41 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Gliosarcoma

## Interventions

- **DRUG:** Avastin
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00979017
- **Lead sponsor:** Katy Peters
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-02
- **Final completion:** 2013-01
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979017, "Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT00979017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*